IDC007 / Prestige BioPharma - LARVOL DELTA

Dual Inhibition of TNF-α and IL-6R mitigates cytokine release syndrome via protection of endothelial integrity and reduction of organ damage in mouse models. (PubMed, Front Immunol) - "To decisively interrupt this inflammatory feedback loop, we developed IDC007, a novel bispecific antibody simultaneously neutralizing TNF-α and IL-6 receptor (IL-6R)...Dual inhibition effectively prevented immune hyperactivation, evidenced by the significant attenuation of splenomegaly and lung-specific organ damage. These findings serve as a preclinical proof-of-concept demonstrating that dual targeting of TNF-α and IL-6R offers a potent mechanistic approach to attenuate severe CRS by preserving vascular endothelial integrity and overcoming the therapeutic limitations of conventional monotherapies."

Journal • Preclinical • Inflammation • Oncology • IFNG • IL6R • TNFA